Sex-specific differences of cardiopulmonary fitness and pulmonary function in exercise-based rehabilitation of patients with long-term post-COVID-19 syndrome.

Sex-specific differences of cardiopulmonary fitness and pulmonary function in exercise-based rehabilitation of patients with long-term post-COVID-19 syndrome.

Publication date: Oct 08, 2024

Post-COVID-19 Syndrome (PCS) entails a spectrum of symptoms, including fatigue, reduced physical performance, dyspnea, cognitive impairment, and psychological distress. Given the effectiveness of exercise-based rehabilitation for PCS, this study examined the efficacy of rehabilitation for PCS patients, focusing on sex-specific differences. Prospective cohort study during inpatient rehabilitation. Cardiopulmonary exercise testing and spirometry were performed at admission and discharge. Questionnaires were used to assess fatigue, health-related quality of life, wellbeing, and workability for up to 6 months. 145 patients (36% female, 47. 1 +/- 12. 7 years; 64% male, 52. 0 +/- 9. 1 years; p = 0. 018) were referred to rehabilitation 262. 0 +/- 128. 8 days after infection (female, 285. 5 +/- 140. 6 days; male, 248. 8 +/- 112. 0 days; p = 0. 110). Lead symptoms included fatigue/exercise intolerance (81. 4%), shortness of breath (74. 5%), and cognitive dysfunction (52. 4%). Women presented with higher relative baseline exercise capacity (82. 0 +/- 14. 3%) than males (68. 8 +/- 13. 3%, p 

Open Access PDF

Concepts Keywords
Fitness Adult
Inpatient Cardiorespiratory Fitness
Intolerance COVID-19
Women Exercise Test
Exercise Therapy
Exercise-based rehabilitation
Fatigue
Fatigue
Female
Humans
Long-COVID
Male
Middle Aged
Post-Acute COVID-19 Syndrome
Prospective Studies
Quality of Life
Respiratory Function Tests
SARS-CoV-2
SARS-CoV-2
Sex Factors

Semantics

Type Source Name
disease MESH COVID-19
disease MESH syndrome
disease MESH dyspnea
disease MESH cognitive impairment
disease MESH psychological distress
disease IDO quality
disease MESH infection
pathway REACTOME Reproduction
disease MESH Long COVID
disease MESH Severe Acute Respiratory Syndrome
disease MESH sequelae
disease IDO acute infection
disease MESH cytokine storm
disease MESH oxidative stress
disease MESH mitochondrial dysfunction
drug DRUGBANK Gold
disease MESH depression
disease IDO history
disease IDO symptom
disease IDO blood
drug DRUGBANK Coenzyme M
drug DRUGBANK Methionine
drug DRUGBANK Trestolone
disease MESH ramp
drug DRUGBANK Oxygen
drug DRUGBANK Carbon dioxide
disease IDO production
disease MESH mental fatigue
disease IDO role
disease MESH general health
disease MESH functional status
disease MESH anxiety
disease MESH metabolic diseases
disease MESH Obesity
disease MESH Hyperlipidemia
disease MESH diabetes mellitus
disease MESH Hypothyroidism
disease MESH hypertension
disease MESH Paroxysmal tachycardia
disease MESH Atrial fibrillation
disease MESH Pulmonary embolism
disease MESH Venous thrombosis
disease MESH Migraine headache
disease MESH adjustment disorders
disease MESH Neoplasms
drug DRUGBANK Aspartame
drug DRUGBANK Hyaluronic acid
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH myocardial infarction
disease MESH multiple sclerosis
disease MESH relapse
drug DRUGBANK Serotonin
disease MESH etiology
disease MESH inflammation
disease MESH hypercoagulability
drug DRUGBANK Etoperidone
disease MESH Allergy
drug DRUGBANK Hydroxyethyl Starch
drug DRUGBANK Diethylstilbestrol
disease MESH viral infection
disease IDO cell

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *